Oct.—Beijing Chemclin Biotech (products to test for infectious diseases or tumors) has raised $16.5mm through the closing of its Series B venture round. New investor China Healthcare Partnership (managed by MC China) led the financing and was joined by current backers SB China Venture Capital, Siemens Venture Capital, and WI Harper. China eCapital was the placement agent.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?